The experimental results of Buchynska et al. (2019) shown that assessment of copy number variations of HER-2/neu, c-MYC and CCNE1 genes revealed their amplification in the tumors of 18.8, 25.0 and 14.3% of endometrial cancer patients, respectively. Here, ERBB2 is linked to endometrial cancer.